These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17008024)

  • 21. Obesity.
    Arterburn D
    Clin Evid; 2004 Jun; (11):762-76. PubMed ID: 15652036
    [No Abstract]   [Full Text] [Related]  

  • 22. Appetite suppressants for obesity.
    Budenholzer B
    J Fam Pract; 1997 Jan; 44(1):19-20. PubMed ID: 9010359
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical experience with the use of phenyltert-butylamine (phentermine) as an appetite depressant in the treatment of obesity].
    Lobato DS; da Silveira DD
    Hospital (Rio J); 1966 Nov; 70(5):1343-50. PubMed ID: 5301950
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D
    Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
    Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats.
    Tallett AJ; Blundell JE; Rodgers RJ
    Behav Brain Res; 2009 Mar; 198(2):359-65. PubMed ID: 19061919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sibutramine: an Australian analysis of reported adverse effects.
    Prescrire Int; 2007 Jun; 16(89):114. PubMed ID: 17590911
    [No Abstract]   [Full Text] [Related]  

  • 29. Sibutramine and psychosis.
    Litvan L; Alcoverro-Fortuny O
    J Clin Psychopharmacol; 2007 Dec; 27(6):726-7. PubMed ID: 18004153
    [No Abstract]   [Full Text] [Related]  

  • 30. New agent for obesity management.
    Schmitt SA
    J Fam Pract; 1996 Sep; 43(3):225. PubMed ID: 8797742
    [No Abstract]   [Full Text] [Related]  

  • 31. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K; Finer N; Rössner S
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of isocaloric diets and sibutramine on food intake, body mass variation and serum TNF-alpha levels in rats.
    Trapali M; Liapi C; Perelas A; Perrea D; Stroubini T; Dontas I; Couvari E; Mavri M; Galanopoulou P
    Pharmacology; 2008; 82(1):15-21. PubMed ID: 18434760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene.
    Hsiao DJ; Wu LS; Huang SY; Lin E
    Pharmacogenet Genomics; 2009 Sep; 19(9):730-3. PubMed ID: 19687782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of weight loss on the metabolic syndrome.
    Phelan S; Wadden TA; Berkowitz RI; Sarwer DB; Womble LG; Cato RK; Rothman R
    Int J Obes (Lond); 2007 Sep; 31(9):1442-8. PubMed ID: 17356528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of an "anorexic" drug (phentermine-resin) in the treatment of obesity].
    Benedetti A; Busonera G; Cattano G
    Policlinico Prat; 1967 Nov; 74(48):1613-9. PubMed ID: 5611163
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation and treatment of obesity.
    Azar ST; Zantout MS
    J Med Liban; 2000; 48(5):310-4. PubMed ID: 12489585
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of lipid lowering effect of sibutramine in patients treated or not treated with statins--3 month follow-up.
    Svacina S; Owen K; Hendl J; Matoulek M; Brychta T
    Prague Med Rep; 2007; 108(4):333-8. PubMed ID: 18780645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M; Liberopoulos EN; Elisaf MS
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
    Vazquez Roque MI; Camilleri M; Clark MM; Tepoel DA; Jensen MD; Graszer KM; Kalsy SA; Burton DD; Baxter KL; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):829-37. PubMed ID: 17544870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.